Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A7 | Q9GZV3 | 2/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4233751 | 0.96 | SLC5A7 (0.44) | SLC5A7ARPGRHRH3OPRK1 | |
| SCHEMBL4238765 | 0.93 | HRH3 (0.47) | SLC5A7HRH3CSF1RFLT3PKM | |
| SCHEMBL4233481 | 0.93 | HRH3 (0.47) | SLC5A7HRH3CSF1RFLT3PKM | |
| SCHEMBL4232714 | 0.91 | SLC5A7 (0.45) | SLC5A7ARPGRHRH3PKM | |
| SCHEMBL4683501 | 0.89 | HRH3 (0.43) | SLC5A7HRH3CSF1RFLT3PKM | |
| SCHEMBL4238304 | 0.87 | SLC5A7 (0.41) | SLC5A7CSF1RFLT3CYP3A4CYP2D6 | |
| SCHEMBL4232082 | 0.86 | HRH3 (0.45) | SLC5A7HRH3CSF1RFLT3 | |
| SCHEMBL4236439 | 0.86 | SLC5A7 (0.45) | SLC5A7ARPGRHRH3OPRK1 | |
| SCHEMBL4743227 | 0.86 | HRH3 (0.40) | SLC5A7ARPGRHRH3PKM | |
| SCHEMBL4683530 | 0.85 | OPRK1 (0.37) | ARPGROPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | SLC5A7 1426/4885AR 1029/4885PGR 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.